
Products And Services
Products And Services
Products and services
Products and services
Indication: This product is suitable to treat the symptoms and signs of Primary Parkinson’s disease in combination with levodopa.
Strength:0.5mg, 3mg (by ropinirole)
Package: Laminated film package, 30 tablets/carton
Validity:24 months
Approval number:0.5mg: National Medicine Standard H20130044
3mg: National Medicine Standard H20130045
The first generic drug consistency evaluation in China
- A new generation of selective ergot dopamine receptor agonists;
- It is recommended as first-line medication for early Parkinson’s treatment by the United States, European and Chinese Parkinson's guidelines.
- Its efficacy and safety are demonstrated by over-20-year clinical medication experience abroad.
- The incidence of dyskinesia in early Parkinson's patients is very low, and it can significantly delay the onset of dyskinesia.
-It assists L-dopa in the treatment of patients with advanced Parkinson’s disease. It can effectively shorten the “day off phenomenon” and reduce 20% of the usage amount of L-dopa.